Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable resid...
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
About this item
Full title
Author / Creator
Heitmann, Jonas S , Schlenk, Richard F , Dörfel, Daniela , Kayser, Sabine , Döhner, Konstanze , Heuser, Michael , Thol, Felicitas , Kapp-Schwoerer, Silke , Labrenz, Jannik , Edelmann, Dominic , Märklin, Melanie , Vogel, Wichard , Bethge, Wolfgang , Walz, Juliane S , Grosse-Hovest, Ludger , Steiner, Martin , Jung, Gundram and Salih, Helmut R
Publisher
BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
About half of AML patients achieving complete remission (CR) display measurable residual disease (MRD) and eventually relapse. FLYSYN is an Fc-optimized antibody for eradication of MRD directed to FLT3/CD135, which is abundantly expressed on AML cells. This first-in-human, open-label, single-arm, multicenter trial included AML patients in CR with p...
Alternative Titles
Full title
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
Authors, Artists and Contributors
Author / Creator
Schlenk, Richard F
Dörfel, Daniela
Kayser, Sabine
Döhner, Konstanze
Heuser, Michael
Thol, Felicitas
Kapp-Schwoerer, Silke
Labrenz, Jannik
Edelmann, Dominic
Märklin, Melanie
Vogel, Wichard
Bethge, Wolfgang
Walz, Juliane S
Grosse-Hovest, Ludger
Steiner, Martin
Jung, Gundram
Salih, Helmut R
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_gale_infotracmisc_A761207972
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A761207972
Other Identifiers
ISSN
1756-8722
E-ISSN
1756-8722
DOI
10.1186/s13045-023-01490-w
